Middle East and Africa Underactive Bladder Market Analysis, Demand & Growth Forecast

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT SEGMENT LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

4.3 EPIDEMIOLOGY

4.4 THE IMPORTANCE OF UNDERSTANDING PATENTS-

4.4.1 DOXAZOSIN

4.4.2 BETHANECHOL CHLORIDE

4.4.3 TAMSULOSIN HYDROCHLORIDE

4.5 CLINICAL TRIALS FOR UNDERACTIVE BLADDER

4.5.1 EU CLINICAL TRIALS REGISTER-

4.6 MERGER & ACQUISITION IN HEALTHCARE INDUSTRY

4.7 M&A DEALS IN 2021 BY TARGET COMPANY TERRITORY:

4.8 CROSS-BORDER DEALS:

4.9 OUTLOOK FOR 2022:

4.1 PATIENT ENROLMENT STRATEGIES

4.11 FACTORS AFFECTING PATIENT RECRUITMENT:

4.12 CHALLENGES:

4.13 PATIENT FUNNEL ANALYSIS:

4.14 RECOMMENDATIONS

4.14.1 USE OF TECHNOLOGY:

4.14.2 PARTICIPANT CHARACTERISTICS:

4.14.3 RECRUITER CHARACTERISTICS:

4.14.4 SYSTEMS & PROCEDURES:

4.14.5 LOCATION:

4.14.6 NATURE OF RESEARCH:

4.15 CONCLUSION:

4.16 UNDERACTIVE BLADDER PATIENT FLOW DIAGRAM

4.17 WHAT CAUSES UNDERACTIVE BLADDER?

4.17.1 CAUSES OF UNDERACTIVE BLADDER INCLUDE

4.17.2 TESTS TO EVALUATE UNDERACTIVE BLADDER

4.18 UNDERACTIVE BLADDER INVESTIGATIONAL PRODUCTS-

5 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASING PREVALENCE OF NEUROGENIC DISORDER

6.1.2 INCREASE IN RESEARCH AND DEVELOPMENT OF UNDERACTIVE BLADDER TREATMENT

6.1.3 FAVOURABLE REIMBURSEMENT SCENARIO

6.1.4 RISING HEALTHCARE EXPENDITURE

6.2 RESTRAINTS

6.2.1 HIGH COST OF RESEARCH AND DEVELOPMENT

6.2.2 STRINGENT GOVERNMENT REGULATIONS ON NEW PRODUCTS APPROVAL

6.3 OPPORTUNITIES

6.3.1 RISING UROLOGIC COMPLICATIONS OF DIABETES

6.3.2 PRESENCE OF NOVEL PIPELINE DRUGS

6.3.3 IMPROVING A BETTER HEALTHCARE SYSTEM

6.4 CHALLENGES

6.4.1 LACK OF PROPER TREATMENT

6.4.2 RISK INVOLVED DURING TREATMENT OF UNDERACTIVE BLADDER

7 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET, BY TYPE

7.1 OVERVIEW

7.2 PHARMACOTHERAPY

7.2.1 ALPHA-BLOCKERS

7.2.2 MUSCARINIC AGONISTS

7.2.3 CHOLINESTERASE INHIBITOR

7.2.3.1 BY DRUGS

7.2.3.1.1 TAMSULOSIN

7.2.3.1.2 DOXAZOSIN

7.2.3.1.3 DISTIGMINE

7.2.3.1.4 BETHANECHOL

7.2.3.1.5 OTHERS

7.2.4 BY PRODUCT TYPES

7.2.4.1 GENERICS

7.2.4.2 BRANDED

7.2.4.2.1 FLOMAX

7.2.4.2.2 ALFADIL

7.2.4.2.3 GRAVITOR

7.2.4.2.4 URIVOID

7.2.4.2.5 OTHERS

7.3 SURGICAL METHODS

7.3.1 SURGICAL NERVE STIMULATION

7.3.2 REDUCTION CYSTOPLASTY

7.3.3 SURGERIES FOR BLADDER OBSTRUCTION

7.3.4 INJECTION INTO EXTERNAL SPHINCTER

7.3.5 OTHERS

7.4 URETHRAL ASSIS DEVICE

7.4.1 INFLOW INTRAURETHRAL VALVE PUMP

7.5 STEM CELL AND GENE THERAPIES

7.5.1 NERVE GROWTH FACTOR

7.5.2 GLIAL-CELL DERIVE NEUTOPHIC FACTORGLIAL

7.5.3 NEUTOPHIN-3 DERIVES FROM GLIALL CELLS

8 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET,BY ROUTE OF ADMINISTRATION

8.1 OVERVIEW

8.2 PARENTERAL

8.3 ORAL

8.4 OTHERS

9 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET , BY END USER

9.1 OVERVIEW

9.2 HOSPITALS

9.3 CLINICS

9.4 ACADEMIC AND RESEARCH

9.5 OTHERS

10 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET , BY DISTRIBUTION CHANNEL

10.1 OVERVIEW

10.2 HOSPITAL PHARMACY

10.3 RETAIL PHARMACY

10.4 OTHERS

11 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET, BY REGION

11.1 MIDDLE EAST AND AFRICA

11.1.1 SOUTH AFRICA

11.1.2 SAUDI ARABIA

11.1.3 U.A.E

11.1.4 ISRAEL

11.1.5 EGYPT

11.1.6 KUWAIT

11.1.7 REST OF MIDDLE EAST AND AFRICA

12 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

13 SWOT ANALYSIS

14 COMPANY PROFILES

14.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

14.1.1 COMPANY SNAPSHOT

14.1.2 COMPANY SHARE ANALYSIS

14.1.3 PRODUCT PORTFOLIO

14.1.4 RECENT DEVELOPMENT

14.2 PFIZER INC.

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 COMPANY SHARE ANALYSIS

14.2.4 PRODUCT PORTFOLIO

14.2.5 RECENT DEVELOPMENT

14.3 SUN PHARMACEUTICAL INDUSTRIES LTD.

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 COMPANY SHARE ANALYSIS

14.3.4 PRODUCT PORTFOLIO

14.3.5 RECENT DEVELOPMENT

14.4 TEVA PHARMACEUTICAL INDUSTRIES LTD

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 COMPANY SHARE ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENT

14.5 NOVARTIS AG

14.5.1 COMPANY SNAPSHOT

14.5.2 REVENUE ANALYSIS

14.5.3 COMPANY SHARE ANALYSIS

14.5.4 PRODUCT PORTFOLIO

14.5.5 RECENT DEVELOPMENT

14.6 DR. REDDY’S LABORATORIES LTD.

14.6.1 COMPANY SNAPSHOT

14.6.2 REVENUE ANALYSIS

14.6.3 PRODUCT PORTFOLIO

14.6.4 RECENT DEVELOPMENT

14.7 ASTELLAS PHARMA INC.

14.7.1 COMPANY SNAPSHOT

14.7.2 REVENUE ANALYSIS

14.7.3 PRODUCT PORTFOLIO

14.7.4 RECENT DEVELOPMENT

14.8 ORION CORPORATION.

14.8.1 COMPANY SNAPSHOT

14.8.2 REVENUE ANALYSIS

14.8.3 PRODUCT PORTFOLIO

14.8.4 RECENT DEVELOPMENT

14.9 ALKEM LABS.

14.9.1 COMPANY SNAPSHOT

14.9.2 REVENUE ANALYSIS

14.9.3 PRODUCT PORTFOLIO

14.9.4 RECENT DEVELOPMENT

14.1 ALMIRALL, S.A

14.10.1 COMPANY SNAPSHOT

14.10.2 REVENUE ANALYSIS

14.10.3 PRODUCT PORTFOLIO

14.10.4 RECENT DEVELOPMENT

14.11 AUROBINDO PHARMA.

14.11.1 COMPANY SNAPSHOT

14.11.2 REVENUE ANALYSIS

14.11.3 PRODUCT PORTFOLIO

14.11.4 RECENT DEVELOPMENT

14.12 CIPLA INC.

14.12.1 COMPANY SNAPSHOT

14.12.2 REVENUE ANALYSIS

14.12.3 PRODUCT PORTFOLIO

14.12.4 RECENT DEVELOPMENT

14.13 GLENWOOD

14.13.1 COMPANY SNAPSHOT

14.13.2 PRODUCT PORTFOLIO

14.13.3 RECENT DEVELOPMENT

14.14 MACLEODS PHARMACEUTICALS LTD.

14.14.1 COMPANY SNAPSHOT

14.14.2 REVENUE ANALYSIS

14.14.3 PRODUCT PORTFOLIO

14.14.4 RECENT DEVELOPMENT

14.15 ONO PHARMACEUTICAL CO., LTD.

14.15.1 COMPANY SNAPSHOT

14.15.2 REVENUE ANALYSIS

14.15.3 PRODUCT PORTFOLIO

14.15.4 RECENT DEVELOPMENT

14.16 VESIFLO, INC.

14.16.1 COMPANY SNAPSHOT

14.16.2 PRODUCT PORTFOLIO

14.16.3 RECENT DEVELOPMENTS

15 QUESTIONNAIRE

16 RELATED REPORTS

List of Table

TABLE 1 TOTAL 40 DOXAZOSIN DRUGS WERE DISCONTINUED FROM THE MARKET

TABLE 2 TOTAL 38 DOXAZOSIN DRUGS ARE STILL IN THE MARKET

TABLE 3 TOTAL PRESCRIPTION AND DISCONTINUED DRUGS (DOXAZOSIN) BY COMPANY

TABLE 4 TOTAL 58 DRUGS DISCONTINUED

TABLE 5 TOTAL PRESCRIPTION AND DISCONTINUED DRUGS (BETHANECHOL CHLORIDE) BY COMPANY

TABLE 6 OUT OF 3,128 STUDIES ON BLADDER DISORDER, ONLY 22 STUDIES ARE ONGOING FOR THE UAB-

TABLE 7 THESE CLINICAL TRIALS ARE MOSTLY RECRUITING/ONGOING IN DIFFERENT REGIONS OF THE WORLD-

TABLE 8 TOP ACQUISITIONS OF 2021 RANKED BY TOTAL DEAL VALUE:

TABLE 9 FDA REQUIRES THE FOLLOWING SCENARIO BEFORE A DRUG IS APPROVED

TABLE 10 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET, TYPE, 2020-2029 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA STEM CELL AND GENE THERAPIES IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET , BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA PARENTERAL IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA ORAL IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET , BY END USER, 2020-2029 (USD MILLION)

TABLE 28 MIDDLE EAST & AFRICA HOSPITALS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 MIDDLE EAST & AFRICA CLINICS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 MIDDLE EAST & AFRICA ACADEMIC AND RESEARCH IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET , BY DISTRIBUTION CHANNEL , 2020-2029 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA HOSPITAL PHARMACY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 MIDDLE EAST & AFRICA RETAIL PHARMACY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 35 MIDDLE EAST & AFRICA OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 36 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 37 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 38 MIDDLE EAST AND AFRICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 39 MIDDLE EAST AND AFRICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 40 MIDDLE EAST AND AFRICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 41 MIDDLE EAST AND AFRICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 42 MIDDLE EAST AND AFRICA BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 43 MIDDLE EAST AND AFRICA BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 44 MIDDLE EAST AND AFRICA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 45 MIDDLE EAST AND AFRICA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 46 MIDDLE EAST AND AFRICA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 47 MIDDLE EAST AND AFRICA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 48 MIDDLE EAST AND AFRICA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 49 MIDDLE EAST AND AFRICA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 50 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 51 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 52 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 53 SOUTH AFRICA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 54 SOUTH AFRICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 55 SOUTH AFRICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 56 SOUTH AFRICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 57 SOUTH AFRICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 58 SOUTH AFRICA BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 59 SOUTH AFRICA BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 60 SOUTH AFRICA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 61 SOUTH AFRICA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 62 SOUTH AFRICA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 63 SOUTH AFRICA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 64 SOUTH AFRICA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 65 SOUTH AFRICA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 66 SOUTH AFRICA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 67 SOUTH AFRICA UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 68 SOUTH AFRICA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 69 SAUDI ARABIA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 70 SAUDI ARABIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 71 SAUDI ARABIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 72 SAUDI ARABIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 73 SAUDI ARABIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 74 SAUDI ARABIA BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 75 SAUDI ARABIA BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 76 SAUDI ARABIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 77 SAUDI ARABIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 78 SAUDI ARABIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 79 SAUDI ARABIA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 80 SAUDI ARABIA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 81 SAUDI ARABIA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 82 SAUDI ARABIA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 83 SAUDI ARABIA UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 84 SAUDI ARABIA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 85 U.A.E UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 86 U.A.E PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 87 U.A.E PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 88 U.A.E BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 89 U.A.E BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 90 U.A.E BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 91 U.A.E BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 92 U.A.E BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 93 U.A.E BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 94 U.A.E BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 95 U.A.E SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 96 U.A.E URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 97 U.A.E STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 98 U.A.E UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 99 U.A.E UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 100 U.A.E UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 101 ISRAEL UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 102 ISRAEL PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 103 ISRAEL PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 104 ISRAEL BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 105 ISRAEL BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 106 ISRAEL BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 107 ISRAEL BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 108 ISRAEL BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 109 ISRAEL BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 110 ISRAEL BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 111 ISRAEL SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 112 ISRAEL URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 113 ISRAEL STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 114 ISRAEL UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 115 ISRAEL UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 116 ISRAEL UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 117 EGYPT UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 118 EGYPT PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 119 EGYPT PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 120 EGYPT BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 121 EGYPT BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 122 EGYPT BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 123 EGYPT BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 124 EGYPT BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 125 EGYPT BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 126 EGYPT BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 127 EGYPT SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 128 EGYPT URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 129 EGYPT STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 130 EGYPT UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 131 EGYPT UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 132 EGYPT UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 133 KUWAIT UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 134 KUWAIT PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 135 KUWAIT PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 136 KUWAIT BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 137 KUWAIT BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 138 KUWAIT BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 139 KUWAIT BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 140 KUWAIT BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 141 KUWAIT BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 142 KUWAIT BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 143 KUWAIT SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 144 KUWAIT URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 145 KUWAIT STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 146 KUWAIT UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 147 KUWAIT UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 148 KUWAIT UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 149 REST OF MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

List of Figure

FIGURE 1 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 9 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: SEGMENTATION

FIGURE 11 INCREASING PREVALENCE OF NEUROGENIC BLADDER INFECTIONS IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET IN THE FORECAST PERIOD

FIGURE 12 TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET IN 2022 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET

FIGURE 14 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : TYPE, 2021

FIGURE 15 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : TYPE, 2022-2029 (USD MILLION)

FIGURE 16 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : TYPE, CAGR (2022-2029)

FIGURE 17 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : TYPE, LIFELINE CURVE

FIGURE 18 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, 2021

FIGURE 19 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)

FIGURE 20 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 21 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 22 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY END USER, 2021

FIGURE 23 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY END USER, 2022-2029 (USD MILLION)

FIGURE 24 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY END USER, CAGR (2022-2029)

FIGURE 25 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY END USER, LIFELINE CURVE

FIGURE 26 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, 2021

FIGURE 27 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 28 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 29 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 30 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET: SNAPSHOT (2021)

FIGURE 31 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET: BY COUNTRY (2021)

FIGURE 32 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET: BY COUNTRY (2022 & 2029)

FIGURE 33 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET: BY COUNTRY (2021 & 2029)

FIGURE 34 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET: BY TYPE (2022-2029)

FIGURE 35 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: COMPANY SHARE 2021 (%)

Frequently Asked Questions

What is the growth rate of the Market?

Middle East and Africa Underactive Bladder Market will grow at a CAGR of 3.5% during the forecast by 2029.

Which factors are poised to restrict the market growth?

The higher cost of R&D for new products demands deep research and clinical studies. The various clinical phases in R&D require huge investments which can affect Middle East and Africa Underactive Bladder Market growth.

Who are the major players operating in the market?

The major players operating in the Middle East and Africa Underactive Bladder Market are Astellas Pharma Inc., Aurobindo Pharma., Boehringer Ingelheim International GmbH, Macleods Pharmaceuticals Ltd., Orion Corporation, Novartis AG, Pfizer Inc., Cipla Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Almirall, S.A, and Alkem Labs. among others.

What are the major countries covered in the Market?

The major countries covered in the Middle East and Africa Underactive Bladder Market are Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, and rest of Middle East and Africa.